$ECTE is poised to grow. Selling on positive news is today's move. Apparently majority of life science investors aren't experts at reading results and become skittish when news appears.
My prediction, within a few trading days, market sentiment will disseminate to portray an accurate representation of the results.
The longs such as myself, who have done all their homework will just buy up all the remains and wait.
With talks of “intensifying” partnership discussions in both the critical care and outpatient settings, commercialization of Symphony, proposed pivotal clinical study, and FDA admission. Echo Therapeutics has a bright future in the booming Diabetes market this year! I can see a 20-30% price adjustment this quarter just from the hype elasticity.
